Here's why Moderna stock soared 125% during the first 6 months of 2021

The COVID-19 vaccine maker has been well rewarded for coming up with a stopgap solution as quickly as it did.

| More on:
share price soaring

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of biopharma Moderna (NASDAQ: MRNA) advanced 124.9% during the first half of this year, according to S&P Global Market Intelligence. The rally extends gains made since early 2020, when the company emerged as a COVID-19 vaccine contender, and then delivered on that promise later in the year.

So what

It's a name that needs little in the way of an introduction. Moderna joins Johnson & Johnson (NYSE: JNJ), Novavax (NASDAQ: NVAX), and a partnership between Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) as the core suppliers of the vaccines aimed at curbing the coronavirus contagion. Moderna's mRNA-1273 was approved by the FDA for emergency use in December of last year, though investors were willing to reward the company before and after that green light. And well they should. Product revenue for the developmental company grew from essentially nothing a year earlier to $1.7 billion for the three-month stretch ending in March, with all of it consisting of COVID vaccine sales. In the meantime, the company has continued to expand on the potential of mRNA-1273 as well as move forward with trials of other vaccine and treatment candidates. It also has other trials underway, such as testing of its mRNA technology as a means of treating cancer, autoimmune disease, and cardiovascular disease -- though for the foreseeable future, evolving strains of COVID will keep the organization busy.

Now what

It's tempting to step into (or stick with) one of the market's hottest biotech stocks that's performing well for all the right reasons. The pandemic could be with us for a while -- perhaps permanently if new strains keep surfacing -- and Moderna's answer thus far appears to be the least problematic. J&J's vaccine has been linked to the development of Guillain-Barre syndrome, while Pfizer's might lead to heart inflammation in rare cases. Moderna's mRNA solution can also cause the same myocarditis, although it's highly effective, and if nothing else, it's increasingly available in an environment where something is better than nothing. With shares up nearly 900% since the coronavirus outbreak went worldwide last year, though, existing shareholders may want to start thinking about an exit plan. While Moderna has provided a beacon of hope, its effort and potential are not only well publicized and fully priced into shares, but they might also be more than priced in. Even the usually aggressive analyst community agrees that shares are only worth on the order of $177 right now, while the stock is trading at a frothy $238.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Should you invest $1,000 in Bhp Group right now?

Before you buy Bhp Group shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Bhp Group wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

James Brumley has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Johnson & Johnson and Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Business woman with her arms folded stands in front of multiple screens.
International Stock News

How did the Magnificent 7 fare this reporting season?

Let's explore the highlights.

Read more »

A man looking at his laptop and thinking.
International Stock News

Amazon: A good quarter but some concerns

Here's our initial take on Amazon's financial report.

Read more »

Man looks up at apple on his head.
International Stock News

Apple: Growth in a difficult environment

Here's our initial take on Apple's financial report.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Why Microsoft stock popped this week

Microsoft stock was up by 9.5% this week.

Read more »

Electric vehicle such as Tesla being charged at charging station.
International Stock News

Tesla searches for Musk successor: Why this matters

Could Elon get the chainsaw from his own board?

Read more »

customers inside and outside a Microsoft retail store
International Stock News

Microsoft shares earnings report: What's the verdict?

Investors moved the Microsoft share price significantly.

Read more »

Warren Buffett
International Stock News

Countdown to Berkshire's AGM: What do investors expect to hear from Warren Buffett this year?

All eyes will be on Omaha, Nebraska this weekend.

Read more »

A smiling woman holds a Facebook like sign above her head.
International Stock News

Meta surges on blockbuster earnings report

It's a good day to be a Meta investor.

Read more »